- New implants leverage existing PRIMA design with significant increase in spatial resolution
- Potential to restore vision to levels sufficient for face recognition and reading smaller fonts: 20/100 with no magnification and up to 20/20 with electronic magnification
- Data on the new implants published in top-tier scientific journals Nature Communications and
Journal of Neural Engineering - Program developed in collaboration with academic partner
Stanford University , where Pixium holds the worldwide exclusive license
- A high-resolution prosthetic vision based on a novel design of a photovoltaic array, where field confinement is achieved by dynamic current steering
- Computational modeling of the field confinement in such an optically controlled circuit validated by in vitro and in vivo measurements
- The grating acuity in vivo with 40mm pixels matches the pixel pitch, while with 20mm pixels it reaches the 28mm limit of the natural visual resolution in rats
- Customized field shaping adapting to individual retinal thickness and distance from the implant, paving the way to higher acuity of prosthetic vision in AMD patients
These results pave the way to prosthetic vision with acuity exceeding 20/100, over five times higher than the current best prosthetic acuity, and with electronic magnification, it may reach 20/20.
The full paper is available online here.
"Our new second generation PRIMA implant represents a huge leap forward in prosthetic vision and offers a real chance to restore sight close to natural vision in patients blinded by retinal degeneration," said
These next generation implants are now being optimized for clinical trials, which could be initiated within the next couple of years. They are based on the design of the original PRIMA implants, which were also co-developed by
"Pixel size limit of the PRIMA implants: from humans to rodents and back" outlines how an increase in the width of the PRIMA implant from 2 to 3 mm and a reduction in the pixel size from 100 to 75mm would nearly quadrupole the number of pixels, which would be very beneficial for patients by increasing their field of view.
The full paper is available online here.
"Photovoltaic implant simulator reveals resolution limits in subretinal prosthesis" demonstrated that by utilizing monopolar pixels as both anodes and cathodes to suppress crosstalk, most patients may achieve resolution no worse than 48mm. Closer proximity between the electrodes and the inner nuclear layer enhances the stimulus strength and contrast and may enable 24mm resolution with 20mm pixels, at least in some patients. A resolution of 24mm on the retina corresponds to 5 times higher acuity than the clinical average with the current implant, promising a significant improvement of central vision for many AMD patients.
The full paper is available online here.
"We are very pleased with the current clinical results and with the progress we are making with Pixium Vision in the development of the next generation of PRIMA implants, described in these three peer-reviewed papers," said Professor
About
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Chief Financial Officer investors@pixium-vision.com +33 1 76 21 47 68 | Media Relations sophie@lifesciadvisors.com +33 6 27 74 74 49 | Investor Relations gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
![](https://ml-eu.globenewswire.com/media/NWU3MmRiOWUtYzBlZC00ZWFmLWEwNTktODNiODMyN2VlNjliLTExMzQ0MTk=/tiny/Pixium-Vision.png)
2023 GlobeNewswire, Inc., source